NEU 3.32% $20.52 neuren pharmaceuticals limited

Ann: AGM Chairman's Address and CEO Presentation, page-14

  1. 264 Posts.
    lightbulb Created with Sketch. 12
    I think the issue with the stock now is that material news which is Phase 3 trofinetide results in 2HCY21 are more than 12 months away. In between the IND approval and start of Phase 2 NNZ-2591 will be positive but unlikely to be a huge stock mover.. A bit more longer horizon and patience required with this one now..
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.